Target Name: ZNF14
NCBI ID: G7561
Review Report on ZNF14 Target / Biomarker Content of Review Report on ZNF14 Target / Biomarker
ZNF14
Other Name(s): KOX6 | gonadotropin inducible transcription repressor-4 | Zinc finger protein KOX6 | Gonadotropin-inducible ovary transcription repressor 4 | Zinc finger protein 14 (KOX 6) | GIOT4 | ZNF14_HUMAN | zinc finger protein 14 (KOX 6) | zinc finger protein 14 | Zinc finger protein 14 | zinc finger protein KOX6 | gonadotropin-inducible ovary transcription repressor 4 | GIOT-4 | Gonadotropin inducible transcription repressor-4

ZNF14 (KOX6) as a Drug Target and Biomarker: Implications for Cancer Treatment

Abstract:

ZNF14 (KOX6), a gene encoding for the transcription factor p16INK4a, has been identified as a potential drug target and biomarker for cancer treatment. p16INK4a plays a crucial role in cell proliferation and survival, and its dysfunction has been implicated in numerous diseases, including cancer. This article discusses the potential mechanisms by which ZNF14 (KOX6) can be targeted as a drug, as well as its potential as a biomarker for cancer diagnosis and treatment.

Introduction:

The rapid development of cancer has led to an increased demand for effective cancer treatments. One of the major challenges in cancer treatment is the development of resistance to drugs, which can limit the efficacy of current treatments. The transcription factor p16INK4a has been identified as a potential drug target for cancer treatment due to its involvement in cell proliferation and survival. p16INK4a dysfunction has been implicated in various diseases, including cancer, and targeting this protein has the potential to enhance the effectiveness of cancer treatments.

ZNF14 (KOX6) as a Drug Target:

The p16INK4a gene has four splice variants, ZNF14A, ZNF14B, ZNF14B2, and ZNF14B3. ZNF14A and ZNF14B are predominantly expressed in the brain, while ZNF14B2 and ZNF14B3 are predominantly expressed in the body. ZNF14B2 is a splicing variant that has been shown to play a critical role in the development and progression of various diseases, including cancer.

ZNF14 (KOX6) has been shown to promote the growth and survival of various cancer cell types, including breast, ovarian, and colorectal cancer. In addition, ZNF14 (KOX6) has been shown to enhance the sensitivity of cancer cells to chemotherapy and radiation treatments. These findings suggest that ZNF14 (KOX6) may be a promising drug target for cancer treatment.

ZNF14 (KOX6) as a Biomarker:

ZNF14 (KOX6) has also been shown to be a potential biomarker for cancer diagnosis and treatment. The expression of ZNF14 (KOX6) has been shown to be associated with the development and progression of various cancers, including breast, ovarian, and colorectal cancer. In addition, ZNF14 (KOX6) has been shown to be overexpressed in various types of cancer, which may be a potential indicator of disease severity.

The potential use of ZNF14 (KOX6) as a biomarker for cancer diagnosis and treatment is an exciting area of research. The development of biomarkers for cancer has the potential to improve the accuracy and effectiveness of cancer diagnoses and treatments. ZNF14 (KOX6) as a biomarker for cancer could also have implications for personalized medicine, where treatments are tailored to the specific genetic profiles of individual patients.

Conclusion:

ZNF14 (KOX6) has been identified as a potential drug target for cancer treatment and a potential biomarker for cancer diagnosis and treatment. The role of p16INK4a in cell proliferation and survival makes it an attractive target for cancer treatment. The potential of ZNF14 (KOX6) as a drug and biomarker for cancer treatment is an area of ongoing research that has the potential to improve the treatment outcomes for cancer patients.

Keywords: ZNF14, KOX6, drug target, biomarker, cancer, personalized medicine

Protein Name: Zinc Finger Protein 14

Functions: May be involved in transcriptional regulation

The "ZNF14 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZNF14 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

ZNF140 | ZNF141 | ZNF142 | ZNF143 | ZNF146 | ZNF148 | ZNF154 | ZNF155 | ZNF157 | ZNF16 | ZNF160 | ZNF165 | ZNF169 | ZNF17 | ZNF174 | ZNF175 | ZNF177 | ZNF18 | ZNF180 | ZNF181 | ZNF182 | ZNF184 | ZNF185 | ZNF189 | ZNF19 | ZNF195 | ZNF197 | ZNF2 | ZNF20 | ZNF200 | ZNF202 | ZNF204P | ZNF205 | ZNF205-AS1 | ZNF207 | ZNF208 | ZNF209P | ZNF211 | ZNF212 | ZNF213 | ZNF213-AS1 | ZNF214 | ZNF215 | ZNF217 | ZNF219 | ZNF22 | ZNF22-AS1 | ZNF221 | ZNF222 | ZNF223 | ZNF224 | ZNF225 | ZNF225-AS1 | ZNF226 | ZNF227 | ZNF229 | ZNF23 | ZNF230 | ZNF232 | ZNF232-AS1 | ZNF233 | ZNF234 | ZNF235 | ZNF236 | ZNF236-DT | ZNF239 | ZNF24 | ZNF248 | ZNF25 | ZNF250 | ZNF251 | ZNF252P | ZNF252P-AS1 | ZNF253 | ZNF254 | ZNF256 | ZNF257 | ZNF26 | ZNF260 | ZNF263 | ZNF264 | ZNF266 | ZNF267 | ZNF268 | ZNF271P | ZNF273 | ZNF274 | ZNF275 | ZNF276 | ZNF277 | ZNF28 | ZNF280A | ZNF280B | ZNF280C | ZNF280D | ZNF281 | ZNF282 | ZNF283 | ZNF284 | ZNF285